Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)

NCT00483496 | Completed Phase 2 Results

• 1 other identifier: V00096 CR 205 (ORF)
• Study Type: interventional
• Target: 16
• Locations: 2 countries
• Sites: 3

Brief Summary

Commercially available external photoprotectors (EP) do not provide adequate protection against ultraviolet A (UVA) and visible wavelengths. The proposed medicinal product V0096 CR (formula RV3131A-MV1166) is a broad spectrum EP (bsEP). The rationale for the use of V0096 CR (formula RV3131A-MV1166) in the proposed condition is based on its ability to broadly block the UVA radiations and visible light that are known to trigger solar urticaria (SU).

Conditions

Idiopathic Solar Urticaria

Outcome Measures

Primary Outcomes (1)

• Assessment of the Minimal Urticaria Dose (MUD) on Each Test Site, After Application of the Test Products

  MUD was defined as the minimal dose for occurrence of objective signs of SU (wheal, flare) under exposure to the solar simulator. Results are expressed as photodermatosis protection factor (PPF), calculated by dividing the MUD of protected skin (sessions 2 to 5) by the MUD of the unprotected skin (session 1) in each treatment group. Procedure: At baseline, 4 grids of 8 adjacent test areas on the patient back were defined. The defined test areas of each grid were applied with the respective test products by the investigating staff at the beginning of each session, according to a predefined randomisation schedule. Grids were sequentially irradiated one by one with 1 MUD (session 2) , 3 MUD (session 3) , 5 MUD (session 4), and 7 MUD (session 5), respectively. After product removal at each session, patients were observed for 30 min for the development of SU lesions. Final reading of all areas was performed at the end of each session, by the investigator masked to product site assignment.

  During each one of the 5 sessions, at study day

Secondary Outcomes (1)

• Adverse Events

  through study completion

Study Arms (1)

V0096CR actives and vehicle

EXPERIMENTAL

Each patient received each one of the 8 test products on their respective randomly allocated sites on grid (grid to be applied on the back skin; 1 product by grid window). Single application of the test materials at the dosage of 2mg/cm² (total of 8 treated sites), prior to irradiation using a solar simulator.

Drug: Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209); Drug: Ti02 pigmentary 3% alone (formula RV3131A-MV1211); Drug: bisoctrizole 10% alone (formula RV3131A-MV1237); Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213); Drug: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329); Drug: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212); Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]; Drug: V0096 CR vehicle (formula RV3131A-MV1197)

Interventions

Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209) DRUG

V0096CR actives and vehicle

Ti02 pigmentary 3% alone (formula RV3131A-MV1211) DRUG

V0096CR actives and vehicle

bisoctrizole 10% alone (formula RV3131A-MV1237) DRUG

V0096CR actives and vehicle

Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213) DRUG

V0096CR actives and vehicle

Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329) DRUG

V0096CR actives and vehicle

Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212) DRUG

V0096CR actives and vehicle

Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)] DRUG

V0096CR actives and vehicle

V0096 CR vehicle (formula RV3131A-MV1197) DRUG

V0096CR actives and vehicle

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female voluntary patients at least 18 years old
• For female patients with child-bearing potential, negative pregnancy test at baseline
• Patients with a clinical and photobiological diagnosis of idiopathic SU
• Patients with no underlying condition, or with underlying conditions provided that these conditions are stable and under control
• Patients able to follow instructions
• Written informed consent from the patients

You may not qualify if:

• Children (less than 18 years old)
• Pregnant or lactating women
• Women with a positive pregnancy test at baseline
• Patients with spontaneous occurrence of SU lesions on the back within 3 days prior to study entry
• Patients with a known allergy to one of the ingredients contained in the test products
• Patients who have applied EP to back skin over the previous 2 weeks before study entry
• Patients who have applied topical corticosteroids to back skin within 7 days prior to study entry
• Patients who have applied an emollient including white soft paraffin on back skin within 2 days prior to study entry
• Patients with systemic exposure to corticosteroids, anti-inflammatories or other immunosuppressive agents within the last 4 weeks prior to study entry
• Patients with oral antihistamines within the last 2 days prior to study entry
• Patients who have been administered systemic or topical photoactive medications for phototherapy or phototherapy alone within 1 week prior to study entry
• Patients with an unstable or non-controlled underlying condition
• Patients who are not able to follow instructions
• Patients who have participated in a study within the 3 months prior to study entry
• Patients who refuse to give written informed consent

Sponsors & Collaborators

• Orfagen: lead

Study Sites (3)

Henry Ford Medical Center

Detroit, Michigan, 48202-2689, United States

Location

St Luke's Roosevelt Hospital Center

New York, New York, 100025, United States

Location

Ninewells Hospital

Dundee, DD19SY, United Kingdom

Location

MeSH Terms

Interventions

titanium dioxide; Single Person

Intervention Hierarchy (Ancestors)

Marital Status; Family Characteristics; Demography; Population Characteristics; Socioeconomic Factors

Results Point of Contact

• Title: Clinical project manager
• Organization: Orfagen

caroline.miklaszewski@orfagen.com

0033534506462

Study Officials

• Patrick Dupuy, Dr

  Orfagen

  STUDY DIRECTOR

• James Ferguson, Pr

  Ninewells Hospital

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 6, 2007
• First Posted: June 7, 2007
• Study Start: September 1, 2007
• Primary Completion: April 1, 2008
• Study Completion: April 1, 2008
• Last Updated: December 22, 2017
• Results First Posted: March 31, 2014

Record last verified: 2017-11

Locations

GB (1); US (2)